Hyperglycaemia and vitamin D: A systematic overview

Current Diabetes Reviews

Volumn 8, Issue 1, 2012, Pages 18-31

  Neil Thomas, G ^a   Scragg, R ^b   Jiang, Chao Q ^c   Chan, Will ^d   März, Winfried ^e,f,g   Pilz, Stefan ^e   Kim, Hyeon C ^h   Tomlinson, Brian ⁱ   Bosch, Jos ^a   Lam, Tai H ^d   Cheung, Bernard M Y ^a   Cheng, Kar K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Guangzhou No 12 Hospital   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g SYNLAB ACADEMY   (Germany)

^h Yonsei University College of Medicine   (South Korea)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Calcium; Hyperglycaemia; Parathyroid hormone; Vascular disease vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; INSULIN; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION (PARAMETERS); CUTANEOUS PHOTOSYNTHESIS; DIABETES MELLITUS; DIET; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MORTALITY; NONHUMAN; PHOTOSYNTHESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY;

EID: 84862910469     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912798829223     Document Type: Article

References (146)

1. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003; 88: 296-307.
2. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-91.
3. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011; 96: E447-52.
4. Holick MF. Vitamin D deficiency. NEJM 2007; 357: 266-81.
5. Glerup H, Mikkelsen K, Poulsen L, et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000; 247: 260-8.
6. Calvo MS, Whiting SJ, Barton CN. Vitamin D Intake: A Global Perspective of Current Status. J Nutr 2005; 135: 310-6.
7. Macdonald HM, Mavroeidi A, Fraser WD, et al. Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes: a major cause for concern? Osteoporos Int 2010; Epub ahead of print.
8. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-8.
9. Loomis WF. Skin-pigment regulation of vitamin-D biosynthesis in man. Science 1967; 157: 501-6.
10. Scragg R, Camargo CA. Frequency of leisure time physical activity and serum 25-hydroxyvitamin D levels in the U.S. population: Results from The Third National Health and Nutrition Examination Survey. Am J Epidemiol 2008; 168: 577-86.
11. Nowson C, Margerison C. Vitamin D intake and vitamin D status of Australians. Med J Aust 2002; 177: 149-52.
12. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28.
13. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501.
14. Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007; 103: 620-5.
15. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577-82.
16. Lips P, Duong T, Oleksik AM, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212-21.
17. van der Wielen RPJ, Lowik MRH, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207-10.
18. Alagol F, Shihadeh Y, Boztepe H, et al. Sunlight exposure and vitamin D deficiency in Turkish women. J Endocrinol Invest 2000; 23: 173-7.
19. Sedrani SH, Elidrissy AWTH, El Arabi KM. Sunlight and vitamin D status in normal Saudi subjects. Am J Clin Nutr 1983; 38: 129-32.
20. Lu L, Pan A, Hu FB, et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese. Diabetes Care 2009; 32: 1278-83.
21. Harinarayan CV. Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int 2005; 16: 397-402.
22. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-21.
23. Meyer HE, Falch JA, Sogaard AJ, Haug E. Vitamin D deficiency and secondary hyperparathroidism and the association with bone mineral density in persons with Pakistani and Norwegian background living in Oslo, Norway, the Oslo Health Study. Bone 2004; 35: 412-7.
24. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.
25. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3.
26. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profile in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-9.
27. Andress DL. Nonclassical aspects of differential vitamin D receptor activation. Drugs 2007; 67: 1999-2012.
28. Cigolini M, Iagulli M, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722-4.
29. Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention. Hong Kong Med J 2002; 8: 26-32.
30. Rebsamen MC, Sun J, Norman AW, Liao JK. 1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91: 17-24.
31. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88: 327-31.
32. Thomas GN, Tomlinson B. Prevention of macrovascular disease in type 2 diabetic patients: blockade of the Renin-Angiotensinaldosterone system. Curr Diabetes Rev 2008; 4: 63-78.
33. Kimura Y, Kawamura M, Owada M, et al. Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 1999; 38: 31-5.
34. Pilz S, Tomaschitz A, Ritz E, Pieber T. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009; 6: 621-30.
35. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010; 411: 1354-60.
36. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998; 352: 709-10.
37. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Research and Clinical Practice 1989; 11: 141-7.
38. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr 1998; 79: 315-27.
39. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-5.
40. Gedik A, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986; 29: 142-5.
41. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes. Diabetes Res Clin Pract 1995; 27: 181-8.
42. Scragg R, Sowers M, Bell C, Third National Health and Nutrition Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-8.
43. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010; 33: 1379-81.
44. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 2009; 48: 349-54.
45. Bourlon PM, Faure-Dussert A, Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1,25-dihydroxyvitamin D3 repletion in the islets of langerhans of rats. J Endocrinol 1999; 162: 101-9.
46. Riachy R, Vandewalle B, Moerman E, et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006; 11: 151-9.
47. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294: F1059-64.
48. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17: 509-11.
49. Beaulieu C, Kestekian R, Havrankova J, Gascon-Barre M. Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes 1993; 42: 35-43.
50. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29: 650-6.
51. Del Gobbo LC, Song Y, Dannenbaum DA, Dewailly E, Egeland GM. Serum 25-hydroxyvitamin D is not associated with insulin resistance or beta cell function in Canadian Cree. J Nutr 2011; 141: 290-5.
52. Muscogiuri G, Sorice G, Prioletta A, et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) 2010; 18: 1906-10.
53. Bjorkman MP, Sorva AJ, Tilvis RS. Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. Eur J Endocrinol 2008; 158: 749-53.
54. Pilz S, Tomaschitz A, März W, et al. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol 2011; Jun 17.
55. Zemel MB. Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 2002; 21: 146S-51S.
56. Schrager S. Dietary calcium intake and obesity. J Am Board Fam Pract 2005; 18: 205-10.
57. Pereira M, Jacobs DR, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 2002; 287: 2081-9.
58. Sanchez M, de la Sierra A, Coca A, Poch E, Giner V, Urbano-Marquez A. Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. Hypertension 1997; 29: 531-6.
59. Baczynski R, Massry S, Magott M, El Belbessi S, Kohan R, Brautbar N. Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 1985; 28: 722-7.
60. Ni Z, Smogorzewski M, Massry SG. Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology Reviews 1994; 135: 1837-44.
61. Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005; 63: 493-8.
62. Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-5.
63. Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001; 17: 175-80.
64. Wareham NJ, Byrne CD, Carr C, Day NE, Boucher BJ, Hales CN. Glucose tolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997; 46: 1171-7.
65. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-8.
66. Reis JP, von Mühlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-55.
67. Kolek OI, Hines ER, Jones MD, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-42.
68. Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009; 20: 230-6.
69. Mirza MA, Alsiö J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011; 31: 219-27.
70. Hesse M, Fröhlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26: 75-84.
71. Beresford JN, Gallagher JA, Poser JW, Russell RG. Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res 1984; 5: 229-34.
72. Vaishnav R, Beresford JN, Gallagher JA, Russell RG. Effects of the anabolic steroid stanozolol on cells derived from human bone. Clin Sci 1988; 74: 455-60.
73. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-69.
74. Kindblom JM, Ohlsson C, Ljunggren O, et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009; 24: 785-91.
75. Im JA, Yu BP, Jeon JY, Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 2008; 396: 66-9.
76. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 45-9.
77. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension Research 2007; 49: 1063-9.
78. Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010; 59: 242-8.
79. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-9.
80. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106: 963-8.
81. Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care 2010; 33: 2021-3.
82. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167: 1159-65.
83. Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010; 33: 1373-5.
84. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28: 1228-30.
85. Hyppönen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a crosssectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298-305.
86. Kayaniyil S, Vieth R, Harris SB, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011; 96: 168-75.
87. Reis JP, von Mühlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009; 207: 585-90.
88. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174-80.
89. Scragg R, Jackson R, Holdaway I, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990; 19: 559-63.
90. Poole KE, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-5.
91. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39: 2611-3.
92. Zittermann A, Schleithoff SS, Frisch S, et al. Circulating calcitriol concentrations and total mortality. Clin Chem 2009; 55: 1163-70.
93. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-37.
94. Jia X, Aucott LS, McNeill G. Nutritional status and subsequent allcause mortality in men and women aged 75 years or over living in the community. Br J Nutr 2007; 98: 593-9.
95. Ginde AA, Scragg R, Schwartz RS, Camargo Jr CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009; 57: 1595-603.
96. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-9.
97. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-11.
98. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 2010; 33: 2238-43.
99. Bolland MJ, Bacon CJ, Horne AM, et al. Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr 2010; 91: 82-9.
100. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010; 65: 225-36.
101. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
102. Autier P, Gandini S. Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-7.
103. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
104. Baynes KCR, Boucher BJ, Feskens EJM, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40: 344-7.
105. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London. Diabetologia 1995; 38: 1239-45.
106. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006; 29: 2244-6.
107. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type diabetic population. Diabetes Care 2001; 24: 1496.
108. Choi HS, Kim KA, Lim CY, et al. Low serum vitamin D is associated with high risk of diabetes in Korean adults. J Nutr 2011; [Epub ahead of print].
109. Colas C, Garabedian M, Fontbonne A, et al. Insulin secretion and plasma 1,25-(OH)2D after UV-B irradiation in healthy adults. Horm Metab Res 1989; 21: 154-5.
110. Need AG, O'Loughlin PD, Horowitz M, Nordin C. Relationship between fasting serum glucose, age, body mass index, and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol 2005; 62: 738-41.
111. Zhao G, Ford ES, Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among U.S. adults without physiciandiagnosed diabetes: NHANES, 2003-2006. Diabetes Care 2010; 33: 344-7.
112. Kositsawat J, Freeman VL, Gerber BS, Geraci S. Association of A1C levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. Diabetes Care 2010; 33: 1236-8.
113. Cosman F, Morgan DC, Nieves JW, et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-66.
114. Brennan PJ, Greenberg G, Miall WE, Thompson SG. Seasonal variation in arterial blood pressure. Br Med J 1982; 285: 919-23.
115. Tseng CL, Brimacombe M, Xie M, et al. Seasonal patterns in monthly hemoglobin A1c values. Am J Epidemiol 2005; 161: 565-74.
116. Sung KC. Seasonal variation of C-reactive protein in apparently healthy Koreans. International Journal of Cardiology 2006; 107: 338-42.
117. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28: 2926-32.
118. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance. The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-25.
119. Grimnes G, Emaus N, Joakimsen RM, et al. Baseline serum 25-hydroxyvitamin D concentrations in the Tromsø Study 1994-95 and risk of developing type 2 diabetes mellitus during 11 years of follow-up. Diabet Med 2010; 27: 1107-15.
120. Matilla C, Knekt P, Mannisto S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007; 30: 2569-70.
121. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008; 19: 666-71.
122. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 2008; 24: 950-6.
123. Patel P, Poretsky L, Liao E. Lack of effect of subtherapeutic vitamin D treatment on glycemic and lipid parameters in Type 2 diabetes: A pilot prospective randomized trial. J Diabetes 2010; 2: 36-40.
124. Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest 1997; 27: 629-33.
125. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57: 258-61.
126. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994; 59: 1083-7.
127. Nilas L, Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes 1984; 8: 407-11.
128. de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008; 31: 701-7.
129. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-10.
130. Avenell A, Cook JA, MacLennan GS, McPherson GC, RECORD trial group. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009; 38: 606-9.
131. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30: 980-6.
132. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabetes Med 2008; 25: 320-5.
133. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010; 53: 2112-9.
134. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010; 267: 462-72.
135. Parekh D, Sarathi V, Shivane VK, Bandgar TR, Menon PS, Shah NS. Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitu. Endocr Pract 2010; 16: 600-8.
136. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-55.
137. Ljunghall S, Lind L, Lithell H, et al. Treatment with one-alphahydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand 1987; 222: 361-7.
138. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6-18.
139. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89: 552-72.
140. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007; 85: 649-50.
141. Scragg R. Vitamin D and type 2 diabetes: Are we ready for a prevention trial? Diabetes 2008; 57: 2565-6.
142. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Food and Nutrition Board. DRI Dietary reference intakes Calcium Vitamin D. Washington, DC, The National Academies Press. 2011.
143. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1986; 1: 187-92.
144. Nyomba BL, Auwerx J, Bormans V, et al. Pancreatic secretion in man with subclinical vitamin D deficiency. Diabetologia 1986; 29: 34-8.
145. Kumar S, Davies M, Zakaria Y, et al. Improvement in glucose tolerance and b-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994; 70: 440-3.
146. Taylor AV, Wise PH. Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J 1998; 74: 365-6.